Definitive Contract HHSN272201600028C
Award Date
9/19/16
Potential Completion Date
9/30/22
Potential Value
$29M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Abviro LLC
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Bethesda, MD 20814, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
13
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health within the Department of Health and Human Services, to Abviro LLC. The $9,765,148 contract is for Abviro to conduct a Phase 2 human challenge clinical trial of its anti-dengue monoclonal antibody product, AV-1. This contract was awarded under a Broad Agency Announcement from NIAID seeking proposals for vaccine candidates, therapeutics, and...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $31,202.00 fixed-price level of effort contract is for process development of vaccine candidates, including for SARS-CoV-2. The award has an ultimate completion date of April 15, 2025. ABL has been awarded multiple indefinite...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside designation....
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a 4-year, $16,905,516 cost-plus-fixed-fee definitive contract to Abvacc, Inc., a for-profit biotechnology company, to develop a potent therapeutic monoclonal antibody targeting the Marburg virus. This contract is part of NIAID's Omnibus Broad Agency Announcement, which seeks research and development of vaccines, therapeutics, and medical countermeasures for infectious diseases. No set-aside designation was used....
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...
This is a firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), for a CUSTOM ANTIBODY PROJECT. The contract was awarded to Aves Laboratories, a self-certified small disadvantaged, woman-owned, Asian-Pacific American-owned business, on March 22, 2016 with a completion date of April 21, 2016 and a ceiling value of $33,917.00. The contract does not have a set-aside...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Fraunhofer USA, Inc. for the development of influenza virus-like particles in a plant-based system. The contract has a ceiling value of $364,793 and a period of performance that ends on March 29, 2017. The contract was not set aside for a specific business type. Fraunhofer USA, Inc. is the...